Loading...
XOSL
NAVA
Market cap37mUSD
May 02, Last price  
21.90NOK
1D
0.00%
1Q
-10.25%
Jan 2017
117.41%
IPO
42.40%
Name

Navamedic ASA

Chart & Performance

D1W1MN
P/E
299.86
P/S
0.73
EPS
0.07
Div Yield, %
Shrs. gr., 5y
8.55%
Rev. gr., 5y
23.00%
Revenues
531m
+3.80%
4,431,931386,45131,835,47846,105,18752,593,12155,092,14371,299,22288,683,865151,772,586223,067,740248,348,362274,297,760257,920,665184,021,794188,754,922209,877,000278,439,000382,135,000511,997,000531,436,000
Net income
1m
-60.96%
-4,866,663-7,572,040-3,211,794-8,076,59912,815,855-11,187,617-7,159,041-3,254,949-1,267,9991,306,185-10,931,730-10,658,412-15,542,4617,283,775-16,297,223-16,460,000618,00029,432,0003,304,0001,290,000
CFO
38m
+1,660.35%
-3,114,131-10,740,7465,557,727-10,660,689-1,646,961-13,463,669-95,521-6,473,430-15,650,876-10,748,49922,628,650-14,508,25159,073,633-36,023,97812,722,136-3,180,000-1,300,00017,941,0002,179,00038,358,000
Dividend
Apr 13, 20101 NOK/sh
Earnings
Jun 04, 2025

Profile

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
IPO date
Mar 31, 2006
Employees
45
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
531,436
3.80%
511,997
33.98%
382,135
37.24%
Cost of revenue
322,559
370,827
267,075
Unusual Expense (Income)
NOPBT
208,877
141,170
115,060
NOPBT Margin
39.30%
27.57%
30.11%
Operating Taxes
3,865
7,529
13,074
Tax Rate
1.85%
5.33%
11.36%
NOPAT
205,012
133,641
101,986
Net income
1,290
-60.96%
3,304
-88.77%
29,432
4,662.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,262
1,198
BB yield
-0.35%
-0.20%
Debt
Debt current
38,309
70,381
15,709
Long-term debt
106,187
109,704
53,717
Deferred revenue
Other long-term liabilities
1,000
(1)
(1,000)
Net debt
91,017
92,900
5,036
Cash flow
Cash from operating activities
38,358
2,179
17,941
CAPEX
(2,198)
(2,251)
Cash from investing activities
(2,778)
(104,583)
(25,444)
Cash from financing activities
83,235
10,074
FCF
218,148
138,474
76,284
Balance
Cash
53,479
38,036
64,390
Long term investments
49,149
Excess cash
26,907
61,585
45,283
Stockholders' equity
29,815
22,294
Invested Capital
380,372
366,317
245,417
ROIC
54.91%
43.69%
43.57%
ROCE
53.73%
34.82%
42.98%
EV
Common stock shares outstanding
17,668
17,613
17,022
Price
25.70
-29.97%
36.70
5.16%
34.90
2.65%
Market cap
454,067
-29.75%
646,393
8.81%
594,082
7.22%
EV
545,084
739,293
599,118
EBITDA
208,877
153,096
122,302
EV/EBITDA
2.61
4.83
4.90
Interest
14,337
612
Interest/NOPBT
10.16%
0.53%